Acta Neuropathologica

, Volume 121, Issue 2, pp 279–281 | Cite as

R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1α upregulation in adult glioma

  • Susan C. Williams
  • Matthias A. Karajannis
  • Luis Chiriboga
  • John G. Golfinos
  • Andreas von Deimling
  • David ZagzagEmail author

Mutations affecting codon 132 of the enzyme cytosolic isocitrate dehydrogenase 1 (IDH-1) have been found in 68–86% of World Health Organization (WHO) grade II and III astrocytic and oligodendroglial tumors in adults, as well as in the majority of WHO grade IV secondary glioblastomas that evolved from these lower-grade tumors [3, 4, 8]. IDH-1 is localized in the cytoplasm and peroxisomes and serves as a major source for cytosolic nicotinamide adenine dinucleotide phosphate (NADPH). NADPH is necessary for the regeneration of reduced glutathione, which functions as the main antioxidant in mammalian cells. Glioma-specific mutations in IDH-1 usually affect the amino acid arginine at position 132 of the amino acid sequence [3, 5, 8], resulting in a substitution of histidine for arginine. This mutation only affects one allele and results in a decrease in IDH-1 activity. Inactivation of IDH-1 has been linked to elevated oxidative stress, which has been hypothesized to confer an increased...


Nicotinamide Adenine Dinucleotide Phosphate Oligodendroglial Tumor Secondary Glioblastoma Primary GBMs Mutant Glioma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work was supported by grants to D.Z. from the National Institutes of Health (R01 CA100426 and R21 NS065280-01) and the Musella Foundation.


  1. 1.
    Capper D, Weissert S, Balss J et al (2010) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20:245–254CrossRefPubMedGoogle Scholar
  2. 2.
    Dang L, White DW, Gross S et al (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739–744CrossRefPubMedGoogle Scholar
  3. 3.
    Ichimura K, Pearson DM, Kocialkowski S et al (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11:341–347CrossRefPubMedGoogle Scholar
  4. 4.
    Metellus P, Coulibaly B, Colin C et al (2010) Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 120:719–729CrossRefPubMedGoogle Scholar
  5. 5.
    Sanson M, Marie Y, Paris S et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150–4154CrossRefPubMedGoogle Scholar
  6. 6.
    Semenza GL (2010) Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29:625–634CrossRefPubMedGoogle Scholar
  7. 7.
    Schofield CJ, Ratcliffe PJ (2004) Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 5:343–354CrossRefPubMedGoogle Scholar
  8. 8.
    Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773CrossRefPubMedGoogle Scholar
  9. 9.
    Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL (2000) Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88:2606–2618CrossRefPubMedGoogle Scholar
  10. 10.
    Zhao S, Lin Y, Xu W et al (2009) Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α. Science 324:261–265CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Susan C. Williams
    • 1
    • 7
  • Matthias A. Karajannis
    • 2
    • 6
    • 7
  • Luis Chiriboga
    • 3
    • 6
    • 7
  • John G. Golfinos
    • 1
    • 6
    • 7
  • Andreas von Deimling
    • 8
    • 9
  • David Zagzag
    • 1
    • 4
    • 5
    • 6
    • 7
    Email author
  1. 1.Department of NeurosurgeryNew York University School of MedicineNew YorkUSA
  2. 2.Division of Pediatric Hematology/Oncology, Department of PediatricsNew York University School of MedicineNew YorkUSA
  3. 3.Immunohistochemistry CoreNew York University School of MedicineNew YorkUSA
  4. 4.Division of Neuropathology, Department of PathologyNew York University School of MedicineNew YorkUSA
  5. 5.Microvascular and Molecular Neuro-oncology LaboratoryNew York University School of MedicineNew YorkUSA
  6. 6.New York University Cancer InstituteNew York University School of MedicineNew YorkUSA
  7. 7.New York University Langone Medical CenterNew York University School of MedicineNew YorkUSA
  8. 8.Department of NeuropathologyRuprecht-Karls-University HeidelbergHeidelbergGermany
  9. 9.Clinical Cooperation Unit NeuropathologyGerman Cancer Research CenterHeidelbergGermany

Personalised recommendations